Dilated Cardiomyopathy Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dilated Cardiomyopathy pipeline constitutes 8+ key companies continuously working towards developing 8+ Dilated Cardiomyopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Dilated Cardiomyopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dilated Cardiomyopathy Market.

The Dilated Cardiomyopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dilated Cardiomyopathy Pipeline Report: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dilated Cardiomyopathy treatment therapies with a considerable amount of success over the years.
• Dilated Cardiomyopathy companies working in the treatment market are Solid Biosciences Inc., DiNAQOR, Heartseed, Bristol-Myers Squibb, Berlin Cures, Pfizer, Bristol-Mayers Squibb, Capricor Therapeutics, Cumberland Pharmaceuticals, and others, are developing therapies for the Dilated Cardiomyopathy treatment
• Emerging Dilated Cardiomyopathy therapies in the different phases of clinical trials are- AVB-401, DINA-006, HS-001, Danicamtiv, BC 007, PF-07265803/ARRY-371797, MYK-491, CAP-1002, Ifetroban, and others are expected to have a significant impact on the Dilated Cardiomyopathy market in the coming years.
• In June 2025, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a late-stage biotechnology company focused on developing genetic therapies for rare diseases with significant unmet needs, has announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for RP-A701. This AAVrh.74-based gene therapy is being developed to treat BAG3-associated Dilated Cardiomyopathy (BAG3-DCM), a serious heart condition marked by progressive enlargement of the ventricles and reduced systolic function.
• In June 2025, Nuevocor, a biotechnology company based in Singapore focused on developing treatments for cardiomyopathies linked to abnormal mechanobiology, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for NVC-001. This AAV-based gene therapy is intended to treat LMNA-related dilated cardiomyopathy (LMNA DCM). The company plans to launch an open-label, dose-escalation Phase 1/2 clinical trial of NVC-001 in patients affected by LMNA DCM.
• In June 2025, Singapore-based Nuevocor has secured FDA clearance for its Investigational New Drug (IND) application for NVC-001, a gene therapy based on an adeno-associated virus (AAV) vector aimed at treating LMNA-related dilated cardiomyopathy (LMNA DCM). Following this approval, the company plans to initiate a first-in-human Phase 1/2 dose-escalation clinical trial. Set to begin early next year, the 52-week study will involve adult participants who will receive a single intravenous dose of the gene therapy.
• In April 2025, Affinia Therapeutics, a gene therapy company focused on developing first-in-class and best-in-class AAV-based treatments for severe cardiovascular and neurological conditions, announced that it will present new preclinical data at the 28th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting, taking place May 13-17, 2025, in New Orleans and online. Presentations will highlight findings from its lead candidate AFTX-201 for BAG3 dilated cardiomyopathy (DCM), innovative AAV capsids targeting central nervous system (CNS) disorders, and its advanced high-yield manufacturing platform.
• In November 2024, Secretome Therapeutics, a biotech firm focused on developing therapies from neonatal cardiac progenitor cells (nCPCs), has successfully secured $20.4 million in funding. This financing will support the initiation of clinical trials for its leading asset, STM-01, and drive the progress of its innovative pipeline.

Dilated Cardiomyopathy Overview
Dilated Cardiomyopathy (DCM) is a condition where the heart's ventricles become enlarged and weakened, impairing the heart's ability to pump blood effectively. This leads to a reduction in the heart's pumping capacity, potentially causing symptoms like fatigue, shortness of breath, and fluid retention. DCM can result from genetic factors, viral infections, high blood pressure, or excessive alcohol use, among other causes. Treatment typically involves managing symptoms with medications, lifestyle changes, and in some cases, surgical interventions such as heart transplants.

Get a Free Sample PDF Report to know more about Dilated Cardiomyopathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Dilated Cardiomyopathy Drugs Under Different Phases of Clinical Development Include:
• AVB-401: Solid Biosciences Inc.
• DINA-006: DiNAQOR
• HS-001: Heartseed
• Danicamtiv: Bristol-Myers Squibb
• BC 007: Berlin Cures
• PF-07265803/ARRY-371797: Pfizer
• MYK-491: Bristol-Mayers Squibb
• CAP-1002: Capricor Therapeutics
• Ifetroban: Cumberland Pharmaceuticals

Dilated Cardiomyopathy Route of Administration
Dilated Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Dilated Cardiomyopathy Molecule Type
Dilated Cardiomyopathy Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Dilated Cardiomyopathy Pipeline Therapeutics Assessment
• Dilated Cardiomyopathy Assessment by Product Type
• Dilated Cardiomyopathy By Stage and Product Type
• Dilated Cardiomyopathy Assessment by Route of Administration
• Dilated Cardiomyopathy By Stage and Route of Administration
• Dilated Cardiomyopathy Assessment by Molecule Type
• Dilated Cardiomyopathy by Stage and Molecule Type

DelveInsight's Dilated Cardiomyopathy Report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Dilated Cardiomyopathy product details are provided in the report. Download the Dilated Cardiomyopathy pipeline report to learn more about the emerging Dilated Cardiomyopathy therapies
https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Dilated Cardiomyopathy Therapeutics Market include:
Key companies developing therapies for Dilated Cardiomyopathy are - Vericel Corporation, AstraZeneca plc., Pfizer Inc., Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc., t2cure GmbH, MyoKardia and Kasiak Research pvt.ltd., and others.

Dilated Cardiomyopathy Pipeline Analysis:
The Dilated Cardiomyopathy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dilated Cardiomyopathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dilated Cardiomyopathy Treatment.
• Dilated Cardiomyopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dilated Cardiomyopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dilated Cardiomyopathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dilated Cardiomyopathy drugs and therapies
https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dilated Cardiomyopathy Pipeline Market Drivers
• Need of novel treatment, rising incidence of congestive heart failure are some of the important factors that are fueling the Dilated Cardiomyopathy Market.

Dilated Cardiomyopathy Pipeline Market Barriers
• However, lack of pipeline therapies, several associated causes of Dilated Cardiomyopathy and other factors are creating obstacles in the Dilated Cardiomyopathy Market growth.

Scope of Dilated Cardiomyopathy Pipeline Drug Insight
• Coverage: Global
• Key Dilated Cardiomyopathy Companies: Solid Biosciences Inc., DiNAQOR, Heartseed, Bristol-Myers Squibb, Berlin Cures, Pfizer, Bristol-Mayers Squibb, Capricor Therapeutics, Cumberland Pharmaceuticals, and others
• Key Dilated Cardiomyopathy Therapies: AVB-401, DINA-006, HS-001, Danicamtiv, BC 007, PF-07265803/ARRY-371797, MYK-491, CAP-1002, Ifetroban, and others
• Dilated Cardiomyopathy Therapeutic Assessment: Dilated Cardiomyopathy current marketed and Dilated Cardiomyopathy emerging therapies
• Dilated Cardiomyopathy Market Dynamics: Dilated Cardiomyopathy market drivers and Dilated Cardiomyopathy market barriers

Request for Sample PDF Report for Dilated Cardiomyopathy Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Dilated Cardiomyopathy Report Introduction
2. Dilated Cardiomyopathy Executive Summary
3. Dilated Cardiomyopathy Overview
4. Dilated Cardiomyopathy- Analytical Perspective In-depth Commercial Assessment
5. Dilated Cardiomyopathy Pipeline Therapeutics
6. Dilated Cardiomyopathy Late Stage Products (Phase II/III)
7. Dilated Cardiomyopathy Mid Stage Products (Phase II)
8. Dilated Cardiomyopathy Early Stage Products (Phase I)
9. Dilated Cardiomyopathy Preclinical Stage Products
10. Dilated Cardiomyopathy Therapeutics Assessment
11. Dilated Cardiomyopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dilated Cardiomyopathy Key Companies
14. Dilated Cardiomyopathy Key Products
15. Dilated Cardiomyopathy Unmet Needs
16 . Dilated Cardiomyopathy Market Drivers and Barriers
17. Dilated Cardiomyopathy Future Perspectives and Conclusion
18. Dilated Cardiomyopathy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Dilated Cardiomyopathy Market https://www.delveinsight.com/report-store/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dilated Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Dilated Cardiomyopathy Epidemiology https://www.delveinsight.com/report-store/dilated-cardiomyopathy-dcm-epidemiology-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dilated Cardiomyopathy Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-marke

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.